Gainers
- Vaccitech VACC shares rose 8.5% to $3.2 throughout Friday’s after-market session. The corporate’s market cap stands at $119.3 million.
- Calithera Biosciences CALA shares rose 7.34% to $0.39. The market worth of their excellent shares is at $1.8 million.
- Ocuphire Pharma OCUP shares elevated by 6.45% to $3.63. The market worth of their excellent shares is at $75.5 million.
- Artistic Medical Tech CELZ inventory elevated by 6.12% to $0.59. The corporate’s market cap stands at $8.2 million.
- Sharps Expertise STSS shares rose 5.88% to $1.44. The corporate’s market cap stands at $13.5 million.
- Summit Therapeutics SMMT shares elevated by 4.95% to $3.39. Buying and selling quantity for this safety closed at 174.7K, accounting for 1.9% of its common full-day quantity over the past 100 days. The market worth of their excellent shares is at $716.3 million.
Losers
- Akanda AKAN inventory declined by 9.9% to $0.31 throughout Friday’s after-market session. Akanda’s buying and selling quantity hit 12.9 million shares by shut, accounting for 440.8% of its common quantity over the past 100 days. The market worth of their excellent shares is at $10.5 million.
- Coronary heart Check Laboratories HSCS inventory declined by 9.76% to $0.79. The market worth of their excellent shares is at $6.5 million.
- Zynerba Prescription drugs ZYNE shares declined by 6.48% to $0.62. The corporate’s market cap stands at $29.1 million.
- Quince Therapeutics QNCX shares decreased by 5.56% to $1.02. Right now’s buying and selling quantity for this safety ended up closing at 17.4 million shares, which is 7279.1 % of its common quantity over the past 100 days. The market worth of their excellent shares is at $36.8 million.
- Tivic Well being Programs TIVC shares declined by 5.41% to $0.7. The market worth of their excellent shares is at $6.7 million.
- NanoVibronix NAOV shares fell 5.01% to $0.3. The corporate’s market cap stands at $9.9 million.
See Additionally: www.benzinga.com/cash/best-healthcare-stocks/
This text was generated by Benzinga’s automated content material engine and reviewed by an editor.
© 2023 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
